A new academic and commercial collaboration between The Institute of Cancer Research, the Bellvitge Biomedical Research Institute (Institut d’Investigació Biomèdica de Bellvitge, IDIBELL) and Vivan Therapeutics (My Personal Therapeutics Ltd.) seeks to create cancer drugs less prone to drug resistance, with a particular focus on drugs that could target KRAS.
Altamira Therapeutics Ltd. has entered into a collaboration and option agreement with Heqet Therapeutics srl, a spin-out from King’s College London, to utilize the company’s proprietary Oligophore delivery platform in cardiovascular research.
The U.S. Department of Defense (DOD) has awarded Evotec SE’s subsidiary Just-Evotec Biologics Inc. a contract valued up to US$74 million for the rapid development of monoclonal antibody (MAb)-based drug product prototypes targeting orthopoxviruses.
A group of international partners with expertise in therapeutics, technology, health data management and data science have joined forces to develop a range of digital tools that will predict and monitor dementia. The two-year pilot project launched in the U.K. will see the unique group focus their initial efforts on developing data and digital solutions to complement existing treatments as well as solving issues related to the prediction, prevention, management and treatment of dementia related disorders.
Zymedi Co. Ltd. has signed a clinical cooperative research and development agreement (CRADA) with the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop ZMA-001 for the treatment of pulmonary arterial hypertension (PAH).
Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate on the clinical development of Nephrodi's NDI-5001 for X-linked congenital nephrogenic diabetes insipidus (NDI). NDI-5001 is a kidney-targeted small molecule AMPK activator.
Verve Therapeutics Inc. has entered into an exclusive research collaboration with Eli Lilly and Co. focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp[a]), a risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis and aortic stenosis.
Confo Therapeutics NV has entered into a research collaboration with Abcellera Biologics Inc. for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
RSS
